InflaRx NV (InflaRx NV) Accounts Payable & Accrued Expense : $13.06 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Accounts Payable & Accrued Expense?

InflaRx NV's quarterly accounts payable & accrued expense increased from Jun. 2023 ($5.64 Mil) to Sep. 2023 ($6.40 Mil) and increased from Sep. 2023 ($6.40 Mil) to Dec. 2023 ($13.06 Mil).

InflaRx NV's annual accounts payable & accrued expense declined from Dec. 2021 ($9.69 Mil) to Dec. 2022 ($5.28 Mil) but then increased from Dec. 2022 ($5.28 Mil) to Dec. 2023 ($13.06 Mil).

InflaRx NV Accounts Payable & Accrued Expense Historical Data

The historical data trend for InflaRx NV's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Accounts Payable & Accrued Expense Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

13.79

10.05

9.69

5.28

13.06

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															5.28	4.94	5.64	6.40	13.06

InflaRx NV Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.